Skip to contentV
VitaNova Life Sciences Corp
V
VNOVVitaNova Life Sciences Corp Q4 2021 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$0.00$0.00derived— vs Q4 2020 Net Income-$25.56K-$25.56KderivedN/M vs Q4 2020 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
VitaNova Life Sciences Corp · CIK 1699709 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$25,563N/M Operating Cash Flowderived$0N/M ended Apr 30, 2021 · filed Jul 1, 2021 · 62 d after period end